Pharmacovigilance training for freshers: what to learn, and how to prove it

There is a specific trap at the start of a drug safety career. Almost every entry-level pharmacovigilance job description asks for experience processing cases in a safety database — and a safety database is the one thing you cannot get access to by reading. So candidates arrive able to define an adverse event and recite the seriousness criteria, and then get asked what they did when a case came back from quality review, and the interview ends.

This guide is about closing that gap. It covers what the job actually involves day to day, the six capabilities interviews really test, how to judge a training programme before you give it your time, and what you can build on your own for free. No salary tables and no promises about the job market — just the substance.

Pharmacovigilance is a regulated operation, not a general office function. Every case a company processes may end up in front of an inspector, along with the audit trail showing who entered what and when. That has two consequences for hiring.

• **Training on the job is expensive.** A new joiner works on real cases under a second-person review, so somebody experienced is spending their time on your output. Teams would rather hire someone who has already made the beginner mistakes somewhere else.
• **The tools are not publicly available.** You cannot download a safety database and practise, the way a developer can install a database or a designer can open a drawing tool. Access comes through an employer or a training provider, and nowhere else.

That is why theory-heavy courses under-deliver. They are not wrong — the regulatory framework genuinely matters — they just stop at the point where the interview starts.

Job titles vary — Drug Safety Associate, Case Processor, PV Associate — but at entry level the work is broadly the same: move individual cases through a controlled workflow, accurately, inside the clock. A typical day involves some mix of the following.

• Picking up new reports from the intake queue and checking whether each one is a valid case at all.
• Logging the receipt date, because that is what starts the regulatory reporting clock.
• Checking whether the report is a duplicate of a case already in the database, or a follow-up to one.
• Entering patient, product, event and reporter data into structured fields.
• Coding the reported event in MedDRA and the products in the WHO Drug Dictionary.
• Writing or updating the case narrative so a reviewer can follow the sequence of events.
• Responding to quality-review findings on your own cases, and reviewing someone else's.

If you want a checklist to measure any course against, this is it. The first two are knowledge and can be learned from public material. The last four are judgement, and judgement only comes from doing the work in a system that pushes back on you.

Notice the split. You can prepare for the top row this week, for free. The bottom row is what separates candidates, and it is the row that needs a system.

Pharmacovigilance training is an unregulated market. Some of it is excellent, some of it is a slide deck and a PDF certificate. Use the table below as a checklist — and treat the red-flag column as disqualifying, not as a minor concern.

Price is a poor quality signal in this market, in both directions. Expensive courses are often theory delivered at scale, because theory is cheap to deliver and hands-on access is not. Free courses can be genuinely substantial when the provider has a reason to run them that does not depend on your fee.

The question worth asking is not what it costs but why it exists. A programme funded by course fees is optimised for enrolment volume. A programme run by a company that needs trained people in the industry it sells into is optimised for whether you can actually do the work afterwards. Both models can produce good training; they fail in different directions.

Whatever programme you eventually join, arriving prepared changes what you get out of it. All of the following is public and costs nothing but time.

• **The ICH E2B(R3) implementation guide.** Dense, but it is the actual specification behind the fields you will spend your day filling in.
• **Regulatory guidance on pharmacovigilance practice.** The EU good pharmacovigilance practices modules and the equivalent FDA guidance documents explain the obligations your SOPs are derived from.
• **Causality assessment methods.** Read how the WHO-UMC categories and the Naranjo scale reason about whether a product caused an event.
• **Public adverse event data.** Regulators publish case-level extracts. Reading real reports teaches you how messy actual source data is — which is the single biggest surprise for new joiners.
• **MedDRA structure.** Learn the hierarchy — LLT, PT, HLT, HLGT, SOC — and how a coding decision moves a case between groupings. Note that MedDRA itself is licensed content, so hands-on browser access normally comes via an employer or training provider.

This is worth understanding before an interview, because it comes up. AI-assisted platforms now read inbound reports and pre-populate case fields, propose MedDRA terms, flag likely duplicates and draft narrative text. If your mental model of the job is pure typing, that sounds like the job disappearing. It is closer to the opposite.

What automation removes is the mechanical part — transcribing a PDF into fields. What it leaves, and increases the value of, is judgement: deciding whether the extracted data is right, whether the proposed term reflects what the reporter meant, and whether the case is submittable. Reviewing a machine-drafted case well is a harder skill than typing one, not an easier one, because you have to spot a confident-looking error. See AI-assisted MedDRA coding and AI versus manual ICSR processing for how the workflows differ in practice, and AI case intake for what the assisted intake step looks like in a modern platform.

Practical consequence for your preparation: being able to say why you rejected a suggested code is now a stronger answer than being able to say you coded quickly.

A suggested sequence, not a syllabus — adjust it to the time you actually have. The point is that each week ends with something you can describe in an interview rather than a topic you have read about.

Weeks 4 to 6 are where self-study hits its ceiling. You can learn the logic, but not the feel of doing it under a review gate — which is the argument for finding a programme with real system access.

Nothing exotic, and nothing you can bluff. If you can answer these clearly and say what you would do when unsure, you are interviewing well above the average fresher.

1. 1A report arrives with an event and a product but no identifiable reporter. Is it a valid case? What do you do next?
2. 2What is the difference between a serious case and a severe event?
3. 3How is the reporting clock started, and what can reset or extend it?
4. 4You receive new information on a case submitted last month. What happens to the original case?
5. 5The reporter wrote 'felt like my heart was racing'. How do you approach coding that?
6. 6An E2B(R3) file fails validation. How do you work out whether it is a schema problem or a business-rule problem?
7. 7Your case comes back from quality review with five findings. How do you handle it?
8. 8Why does a safety system keep an audit trail, and what would an inspector look at?

The strongest thing a fresher can say in a drug safety interview is not a definition. It is: I have done this, in a system, and here is what I got wrong the first time.

Start with the free public material above so you arrive with the vocabulary. Then find a way to work real cases in a real system, because that is the part no amount of reading substitutes for. If you want to do that with us, PVgenix Academy runs free live batches and you can apply in about two minutes — small batches, no fee, and no promises we cannot keep.

If you would rather keep reading first, what ICSR case processing involves is the natural next article, and E2B(R2) versus E2B(R3) covers the submission format in detail.